Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14618237rdf:typepubmed:Citationlld:pubmed
pubmed-article:14618237lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C0232338lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C0003018lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C0042401lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C0035331lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C0232105lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:14618237lifeskim:mentionsumls-concept:C1882115lld:lifeskim
pubmed-article:14618237pubmed:issue1lld:pubmed
pubmed-article:14618237pubmed:dateCreated2004-1-16lld:pubmed
pubmed-article:14618237pubmed:abstractTextThe renin angiotensin system is emerging as a potential therapeutic target for diabetic retinopathy. This study examines the effects of angiotensin-converting-enzyme inhibition by captopril and angiotensin AT(1) receptor antagonism using candesartan-cilexetil on retinal blood flow and acetylcholine-stimulated vasodilatation in normotensive diabetic rats.lld:pubmed
pubmed-article:14618237pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:languageenglld:pubmed
pubmed-article:14618237pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:citationSubsetIMlld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14618237pubmed:statusMEDLINElld:pubmed
pubmed-article:14618237pubmed:monthJanlld:pubmed
pubmed-article:14618237pubmed:issn0012-186Xlld:pubmed
pubmed-article:14618237pubmed:authorpubmed-author:HoriiTTlld:pubmed
pubmed-article:14618237pubmed:authorpubmed-author:AbikoTTlld:pubmed
pubmed-article:14618237pubmed:authorpubmed-author:FeenerE PEPlld:pubmed
pubmed-article:14618237pubmed:authorpubmed-author:ClermontA CAClld:pubmed
pubmed-article:14618237pubmed:authorpubmed-author:AbikoAAlld:pubmed
pubmed-article:14618237pubmed:authorpubmed-author:ShoelsonB DBDlld:pubmed
pubmed-article:14618237pubmed:authorpubmed-author:BursellS-ESElld:pubmed
pubmed-article:14618237pubmed:issnTypePrintlld:pubmed
pubmed-article:14618237pubmed:volume47lld:pubmed
pubmed-article:14618237pubmed:ownerNLMlld:pubmed
pubmed-article:14618237pubmed:authorsCompleteYlld:pubmed
pubmed-article:14618237pubmed:pagination113-23lld:pubmed
pubmed-article:14618237pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:meshHeadingpubmed-meshheading:14618237...lld:pubmed
pubmed-article:14618237pubmed:year2004lld:pubmed
pubmed-article:14618237pubmed:articleTitleAngiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats.lld:pubmed
pubmed-article:14618237pubmed:affiliationResearch Division and Beetham Eye Institute, Joslin Diabetes Center and Harvard Medical School, One Joslin Place, Boston, USA.lld:pubmed
pubmed-article:14618237pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14618237pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14618237pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:81638entrezgene:pubmedpubmed-article:14618237lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:14618237lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14618237lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14618237lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14618237lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14618237lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14618237lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14618237lld:pubmed